Others’ Research

Researchers at the Canadian Centre for Applied Research in Cancer Control (ARCC) are conducting other research related to cancer drugs, such as how they are evaluated and how decisions are made about funding them. You can read more about these streams of research on ARCC’s website.

Related Academic Papers – Monthly

March 2020

Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.

Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study.

Decision-Making in Sequential Adaptive Clinical Trials, with Implications for Drug Misclassification and Resource Allocation

February 2020

Global public and philanthropic investment in childhood cancer research: systematic analysis of research funding, 2008–16

Multiplicity in oncology randomised controlled trials: a threat to medical evidence?

The Financial Effect of Medicare Coverage Design and Safety Net Options for Cancer Care.

January 2020

Inclusion of Older Patients with Cancer in Clinical Trials: The SAGE Prospective Multicenter Cohort Survey

Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs

Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology

December 2019

Impact of a novel prioritization framework on clinician-led oncology drug submissions

Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial

Drug funding price negotiations: Towards achieving a balance between individual and population gains in health benefits.

November 2019

How to utilize academic research efforts in cancer drug discovery

The Costs of Industry-Sponsored Drug Trials in Canada

Evaluating Canadians’ Values for Drug Coverage Decision Making

October 2019

Access to Cancer Drugs in Canada: Looking Beyond Coverage Decisions

International variability in the reimbursement of cancer drugs by publically funded drug programs

Health Care Cost Containment Strategies Used In Four Other High-Income Countries Hold Lessons For The United States

September 2019

Addressing the affordability of cancer drugs: using deliberative public engagement to inform health policy

Strategizing health technology assessment for containment of cancer drug costs in a universal health care system: Case of the pan‐Canadian Oncology Drug Review

Conditional approval of cancer drugs in Canada: accountability and impact on public funding

August 2019

Cost of Cancer: Healthcare Expenditures and Economic Impact

Strategies for Progress

Pricing a Year of Progression-Free Survival: When Is the Cost of Cancer Drugs Unreasonable?

July 2019

Approaches to Capturing Value in Oncology

Assessment of External Price Referencing and Alternative Policies

Medicine Prices in the United States and Canada

June 2019

Comparison of numbers and timing of new medication regulatory approvals in Canada and New Zealand

Heterogeneous Recommendations for Oncology Products Among Different HTA Systems: A Comparative Assessment

Orphan Drugs in Oncology

May 2019

Price Studies for Specific Medicines

Therapy of Cancer and Retroviral Diseases

Drug Pricing and Value in Oncology

April 2019

Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.

Prioritization not Rationing in Cancer Care

Medicine Prices in Asia–Pacific Countries

March 2019

AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health

What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries

Balancing the Economics and Ethics of Personalised Oncology

February 2019

New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations

Patient-Reported Outcomes in Health Economic Decision-Making: A Changing Landscape in Oncology

Oncology from an HTA and Health Economic Perspective

January 2019

This is a call to oncologists for action

Cancer drugs in China: affordability and creativity

Three Steps Toward a More Sustainable Path for Targeted Cancer Drugs

December 2018

Financial Toxicity of Cancer Drugs: Possible Remedies from an Ethical Perspective

Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer

Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example

November 2018

Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting

Ethical Hurdles in the Prioritization of Oncology Care

Economic burden of cancer across the European Union: a population-based cost analysis

October 2018

Cancer Drugs in the United States: Justum Pretium—The Just Price

Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015

Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs

September 2018

Trade-offs, fairness, and funding for cancer drugs: key findings from a deliberative public engagement event in British Columbia, Canada

Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs

Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs

August 2018

Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study

The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada

Accurate Measurement of Financial Toxicity Is a Prerequisite to Finding a Remedy

July 2018

A synthesis of drug reimbursement decision-making processes in organisation for economic co-operation and development countries

Timeliness of the oncology drug review process for public funding in Canada

Trends of new cancer drug approvals from the perspective of a publicly funded healthcare system: Analyses of the pan-Canadian Oncology Drug Review (pCODR) recommendations

June 2018

Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs.

Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs

Development of a systematic approach to pharmaceutical industry's patient assistance programs on accessing unfunded cancer drugs

May 2018

Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks

Overcoming obstacles in accessing unfunded oral chemotherapy: physician experience and challenges 

Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States

April 2018

Management of Hospital Formularies in Ontario: Challenges within a Local Health Integration Network

Value Frameworks in Oncology: Comparative Analysis and Implications to the Pharmaceutical Industry

Trends in Financial Access to Prescription Drugs Among Cancer Survivors 

March 2018

Reimbursement of targeted cancer therapies within 3 different European health care systems 

Less than ideal: how oncologists practice with limited drug access

Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints

February 2018

A Much-Needed Corrective on Drug Development Costs

Evaluation of the ASCO Value Framework for Anticancer Drugs at an Academic Medical Center

Variation and consternation: access to unfunded cancer drugs in Canada

January 2018

Responsible pricing in value-based assessment of cancer drugs: real-world data are an inevitable addition to select meaningful new cancer treatments

Country and regional variations in purchase prices for essential cancer medications

A deliberative framework to identify the need for real-life evidence building of new cancer drugs after interim funding decision

December 2017

Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based Pricing

Challenges for clinical trials in oncology within the scope of early benefit assessment of drugs

Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency

November 2017

Cost-Effectiveness Impacts Cancer Care Funding Decisions in British Columbia, Canada, Evidence from 1998 to 2008.

Importance of cost-effectiveness and value in cancer care and healthcare policy

The urgent need to improve the tools to assess clinical benefit and value of cancer treatment

October 2017

Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes

Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales

September 2017

Ethical Hurdles in the Prioritization of Oncology Care

Perspectives on Cost and Value in Cancer Care

Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund

August 2017

Market access of cancer drugs in European countries: improving resource allocation

Access to expensive anti-cancer drugs

How Long Should We Continue the Chemotherapy?-From the View Point of Health Economics

July 2017

A rapidly changing global medicines environment: How adaptable are funding decision-making systems?

Cancer Drugs Provide Positive Value In Nine Countries, But The United States Lags In Health Gains Per Dollar Spent

Lowering the High Cost of Cancer Drugs—III

June 2017

The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study

Postmarket policy considerations for biosimilar oncology drugs

Having “Skin in the Game” and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs

May 2017

The availability of essential cancer medication: An analysis of national formularies

Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System

Toward Value-Based Pricing to Boost Cancer Research and Innovation

April 2017

Assessment of value for resource allocation in cancer care

Value assessment in precision cancer medicine

Alignment of practice guidelines with targeted-therapy drug funding policies in Ontario

March 2017

Costs matter: The impact of disclosing treatment costs and provider profit on patients’ decisions

The right amount of chemotherapy in non-curable disease: Insights from health economics

Costs, Effectiveness, and Cost-Effectiveness of Selected Surgical Procedures and Platforms

February 2017

Value and cancer medicines—A personal view http://www.journalcancerpolicy.net/article/S2213-5383(16)30038-8/fulltext

QALYs as a measure of value in cancer http://www.journalcancerpolicy.net/article/S2213-5383(16)30023-6/fulltext

Physician experience and challenges obtaining unfunded oral chemotherapy across Canada https://www.ncbi.nlm.nih.gov/pubmed/28022096

January 2017

Evidence, value and hope — Allocating resources for cancer http://www.journalcancerpolicy.net/article/S2213-5383(16)30048-0/fulltext

Assessing the value of cancer treatments from real world data—Issues, empirical examples and lessons learnt http://www.journalcancerpolicy.net/article/S2213-5383(16)30039-X/fulltext

Translation of evidence into funding policy: An overview of guidelines from the Cancer Care Ontario's Program in Evidence-Based Care (PEBC) https://www.ncbi.nlm.nih.gov/pubmed/28022266

December 2016

Ethics, Priorities, and Cancer http://www.journalcancerpolicy.net/article/S2213-5383(16)30037-6/fulltext

Value-based payment for oncology services in the United States and France http://www.journalcancerpolicy.net/article/S2213-5383(16)30014-5/fulltext

Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the World http://theoncologist.alphamedpress.org/content/21/8/907.short

November 2016

Affordability of cancer care in the United Kingdom – Is it time to introduce user charges?http://www.journalcancerpolicy.net/article/S2213-5383(13)00019-2/fulltext

Healthcare Financing and the Cost of Cancer Care http://www.cancernetwork.com/practice-policy/healthcare-financing-and-cost-cancer-care

Cancer Drugs Fund requires further reform http://www.bmj.com/content/354/bmj.i5090.abstract

October 2016

Rare cancers—Rarity as a cost and value argument http://www.journalcancerpolicy.net/article/S2213-5383(16)30019-4/fulltext

Financing Cancer Care in Low-Resource Settings https://www.ncbi.nlm.nih.gov/books/NBK343629/

Understanding the value of cancer drugs—the devil is in the detail http://onlinelibrary.wiley.com/doi/10.1002/cncr.30044/full

September 2016

Ontario’s approach to tackling drug funding sustainability.  http://meeting.ascopubs.org/cgi/content/abstract/34/7_suppl/38

Insurance Denial of Coverage for Patients Enrolled in Cancer Clinical Trials Is Still a Problem in the Affordable Care Act Era  http://www.jop.ascopubs.org/content/early/2016/02/18/JOP.2015.010454.extract

Phase-specific healthcare costs of cervical cancer: estimates from a population-based study http://www.sciencedirect.com/science/article/pii/S0002937815023509

August 2016

The politicization of oncology drug funding reviews in Canada http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900824/

Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780589/

Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers http://link.springer.com/article/10.1007/s40271-015-0139-7

July 2016

Global differences in cancer drug prices: A comparative analysis http://meetinglibrary.asco.org/content/164423-176

Provincial elections and timing of cancer drug funding http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900826/

Multiple Dimensions of Value: Evaluative Frameworks for New Cancer Therapies http://jco.ascopubs.org/content/early/2016/02/11/JCO.2015.66.4201.full

June 2016

Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials.  http://jco.ascopubs.org/content/13/9/2457.short

Improving the evaluation of new cancer treatments: challenges and opportunities http://www.nature.com/nrc/journal/v3/n4/abs/nrc1047.html

Priority setting for new technologies in medicine: qualitative case study http://www.bmj.com/content/321/7272/1316?variant=full-text

May 2016

Financial and family burden associated with cancer treatment in Ontario, Canada http://link.springer.com/article/10.1007/s00520-006-0088-8

How Do Cost-Effectiveness Analyses Inform Reimbursement Decisions for Oncology Medicines in Canada? The Example of Sunitinib for First-Line Treatment of Metastatic Renal Cell Carcinoma http://onlinelibrary.wiley.com/doi/10.1111/j.1524-4733.2010.00738.x/full

Improving the evaluation of new cancer treatments: challenges and opportunities http://www.nature.com/nrc/journal/v3/n4/abs/nrc1047.html

April 2016

Prescription Drug Coverage Varies Widely Across Canada http://journals.lww.com/lww-medicalcare/Abstract/2001/04000/A_Dog_s_Breakfast___Prescription_Drug_Coverage.3.aspx

Medication Problems in Older, Newly Diagnosed Cancer Patients in Canada: How Common are They?    http://link.springer.com/article/10.2165/00002512-200926060-00008

Inequalities in oncology care: Economic consequences of high cost drugs http://www.sciencedirect.com/science/article/pii/S0959804906006812?np=y

March 2016

Cancer therapy disparity: unequal access to breast cancer therapeutics and drug funding in Canada http://current-oncology.com/index.php/oncology/article/viewFile/180/153

Funding New Cancer Drugs in Ontario: Closing the Loop in the Practice Guidelines Development Cycle  http://jco.ascopubs.org/content/19/14/3392.short

An examination of cancer patients’ monthly ‘out-of-pocket’ costs in Ontario, Canada http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2354.2007.00783.x/abstract?userIsAuthenticated=false&deniedAccessCustomisedMessage=

February 2016

Cancer Care Ontario's new drug funding program: controlled introduction of expensive anti-cancer drugs    http://search.proquest.com/openview/7e7ef49ea551d0b4aa53fb538554d1b5/1?pq-origsite=gscholar

6-STEPPPs: A Modular Tool to Facilitate Clinician Participation in Fair Decisions for Funding New Cancer Drugs   http://jop.ascopubs.org/content/4/1/2.short

Priority setting in a hospital drug formulary: a qualitative case study and evaluation http://www.sciencedirect.com/science/article/pii/S0168851003000630

January 2016

Informing Canada’s cancer drug funding decisions with scientific evidence and patient perspectives: the Pan-Canadian Oncology Drug Review  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615855/

Accounting for reasonableness: Exploring the personal internal framework affecting decisions about cancer drug funding  http://www.sciencedirect.com/science/article/pii/S0168851007002862

Bringing ‘the public’ into health technology assessment and coverage policy decisions: From principles to practice   http://www.sciencedirect.com/science/article/pii/S0168851006001758

December 2015

Priority-setting decisions for new cancer drugs: a qualitative case study https://www.researchgate.net/profile/Joseph Pater/publication/11626513 Priority-setting decisions for new cancer drugs a qualitative case study/links/54ee08f30cf25238f93970f0.pdf

Public funding of new cancer drugs: Is NICE getting nastier?https://www.researchgate.net/profile/Anne Mason2/publication/23781749 Public funding of new cancer drugs Is NICE getting nastier/links/00b7d5174faef0f17f000000.pdf

International variability in the reimbursement of cancer drugs by publicly funded drug programs http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364777/

November 2015

Continental Divide? The Attitudes of US and Canadian Oncologists on the Costs, Cost-Effectiveness, and Health Policies Associated With New Cancer Drugs http://jco.ascopubs.org/content/28/27/4149.short

Cancer therapy disparity: unequal access to breast cancer therapeutics and drug funding in Canada http://current-oncology.com/index.php/oncology/article/viewFile/180/153

Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions http://jama.jamanetwork.com/article.aspx?articleid=184659

October 2015

Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers                                                                            http://link.springer.com/article/10.1007/s40271-015-0139-7

Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea                                                                         http://www.healthpolicyjrnl.com/article/S0168-8510(15)00027-5/abstract

Development and economic trends in cancer therapeutic drugs: a 5-year update 2010–2014       http://www.nature.com/bjc/journal/v112/n6/full/bjc201556a.html

September 2015

Access to Cancer Drugs in Canada: Looking Beyond Coverage Decisions

International variability in the reimbursement of cancer drugs by publically funded drug programs

Health Care Cost Containment Strategies Used In Four Other High-Income Countries Hold Lessons For The United States

August 2015

Are high drug prices for hematologic malignancies justified? A critical analysis

Cancer care burden: aiming at the Achilles heel

The price of global health: drug pricing strategies to balance patient access and the funding of innovation

July 2015

The price of global health: drug pricing strategies to balance patient access and the funding of innovation   https://www.gowerpublishing.com/pdf/SamplePages/The-Price-of-Global-Health-CH1.pdff

Extending life for people with a terminal illness: a moral right and an expensive death?  Exploring societal perspectives    http://www.biomedcentral.com/content/pdf/s12910-015-0008-x.pdf

Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review     http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461134/

June 2015

A Time-Trend Economic Analysis of Cancer Drug Trials  https://theoncologist.alphamedpress.org/content/early/2015/06/01/theoncologist.2014-0437.abstract

Is There an Economic Rationale for Cancer Drugs to Have a Separate Reimbursement Review Process for Resource Allocation Purposes? http://www.ncbi.nlm.nih.gov/pubmed/?term=Is+There+an+Economic+Rationale+for+Cancer+Drugs+to+Have+a+Separate+Reimbursement+Review+Process+for+Resource+Allocation+Purposes%3F

Improving the Legitimacy of Medicines Funding Decisions: A Critical Literature Review  http://dij.sagepub.com/content/early/2015/04/01/2168479015579519.abstract

May, 2015

Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration  http://onlinelibrary.wiley.com/doi/10.1002/cncr.29246/abstract;jsessionid=71057E24A226394BB70D721B6CB16348.f04t01?deniedAccessCustomisedMessage=&userIsAuthenticated=false

Meaningful patient representation informing Canada’s cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug Review  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189566/

Benefits Outweigh Costs in Universal Healthcare: Business Case for Reimbursement of Take-home Cancer Medicines in Ontario and Atlantic Canada   http://www.kidneycancercanada.ca/media/926488/10.5923.j.ajmms.20140404.05.pdf

What is a new drug worth? An innovative model for performance-based pricing  http://onlinelibrary.wiley.com/doi/10.1111/ecc.12240/full

Leave a Reply